<DOC>
	<DOCNO>NCT00281827</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy , carboplatin gemcitabine , work different way stop growth tumor cell , either kill cell stop dividing . Thalidomide may stop growth tumor cell block blood flow tumor . Giving carboplatin gemcitabine together thalidomide surgery may make tumor small reduce amount normal tissue need remove . PURPOSE : This phase II trial study well give carboplatin gemcitabine together thalidomide work treat patient undergo surgery stage II stage III non-small cell lung cancer .</brief_summary>
	<brief_title>Carboplatin , Gemcitabine , Thalidomide Patients Undergoing Surgery Stage II III Non-Small Cell Lung Cancer</brief_title>
	<detailed_description>OBJECTIVES : Primary - Determine complete partial response rate patient stage II IIIA non-small cell lung cancer treat neoadjuvant carboplatin , gemcitabine hydrochloride , thalidomide . Secondary - Determine , preliminarily , mechanism action activity thalidomide lung cancer . - Determine 1-year 2-year survival patient treat regimen . - Determine toxicity regimen patient . - Determine operative mortality patient treat regimen . OUTLINE : This pilot study . Patients receive carboplatin intravenously ( IV ) 30 minute day 1 , gemcitabine hydrochloride IV 30 minute day 1 8 , oral thalidomide daily day 1-21 . Treatment repeat every 21 day 3 course absence disease progression unacceptable toxicity . Within 2-6 week completion chemotherapy , patient resectable tumor undergo surgical resection . After completion study treatment , patient follow every 3 month 2 year .</detailed_description>
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<mesh_term>Gemcitabine</mesh_term>
	<mesh_term>Thalidomide</mesh_term>
	<mesh_term>Carboplatin</mesh_term>
	<criteria>Histologically cytologically confirm nonsmall cell lung cancer ( NSCLC ) , include follow histologic subtypes : Squamous cell carcinoma Adenocarcinoma Large cell undifferentiated carcinoma Stage II IIIA disease Measurable disease , define ≥ 1 unidimensionally measurable lesion ≥ 20 mm conventional technique OR ≥ 10 mm spiral Computerized Axial Tomography ( CT ) scan No tumor involve superior sulcus ( e.g. , Pancoast tumor ) Karnofsky performance status 70100 % Absolute neutrophil count ≥ 1,500/mm^3 Platelet count ≥ 100,000/mm^3 Creatinine ≤ 2 mg/dL Bilirubin &lt; 2 mg/dL Aspartate aminotransferase ( AST ) &lt; 3 time upper limit normal Pregnant nursing No nursing ≥ 4 week completion study treatment Positive pregnancy test Fertile female patient must use 2 effective method contraception 4 week , , 4 week completion study treatment Fertile male patient must use effective barrier contraception 4 week completion study treatment Blood , sperm , ova donation study treatment Post obstructive pneumonia Other serious infection medical illness would preclude study participation Other malignancy within past 5 year except adequately treat basal cell squamous cell skin cancer , carcinoma situ cervix , malignancy unlikely affect survival next 3 year Less 5 year since prior resection lung disease Prior systemic chemotherapy radiotherapy nonsmall cell lung cancer ( NSCLC ) Other concurrent chemotherapy radiotherapy Concurrent hormonal therapy immunotherapy Other concurrent anticancer therapy Other concurrent investigational agent Concurrent participation another clinical study</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2012</verification_date>
	<keyword>adenocarcinoma lung</keyword>
	<keyword>squamous cell lung cancer</keyword>
	<keyword>large cell lung cancer</keyword>
	<keyword>stage II non-small cell lung cancer</keyword>
	<keyword>stage IIIA non-small cell lung cancer</keyword>
</DOC>